Retroviral coinfections with HIV-1 and HTLV-1 or with HIV-1 and HTLV-2 occur with variable frequencies throughout the world with the highest prevalence in large metropolitan areas in the Americas, Europe, and Africa. The recognition that retroviral coinfections exist dates back to the discovery of HIV-1 over 25 years ago. Despite the large body of published information regarding the biological and clinical significance of retroviral coinfections, controversy throughout several decades of research was fueled by several flawed epidemiologic studies and anecdotal reports that were not always supported with ample statistical and scientific evidence. However, the growing consensus obtained from recent systematic and well-devised research provides support for at least three conclusions: (1) HIV-1 and HTLV-1 coinfections are often seen in the context of patients with high CD4+ T cell counts presenting with lymphoma or neurological complications; (2) HIV-1 and HTLV-2 coinfections have been linked in some cases to a “long term nonprogressor” phenotype; and (3) differential function and/or overexpression of the HTLV-1 and HTLV-2 Tax proteins likely play a pivotal role in the clinical and immunologic manifestations of HIV/HTLV-1 and -2 coinfections. This review will recount the chronology of work regarding retroviral coinfections from 1983 through the present.
Get full access to this article
View all access options for this article.
References
1.
van der KuylAC, CornelissenM. Identifying HIV-1 dual infections. Retrovirology, 2007; 4,67:1–12.
2.
McCutchanFE, HoelscherM, TovanabutraS, PiyasirisilpS, Sanders-BuellE, RamosG, JagodzinskiL, PolonisV, MabokoL, MmbandoD, HoffmannO, RiednerG, von SonnenburgF, RobbM, BirxDL. In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: Evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection. J Virol, 2005; 79,18:11693–11704.
3.
TaylorJE, KorberBT. HIV-1 intra-subtype superinfection rates: Estimates using a structured coalescent with recombination. Infect Genet Evol, 2005; 5,1:85–95.
4.
ChakrabortyB, ValerL, De MendozaC, SorianoV, Quinones-MateuME. Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Res Hum Retroviruses, 2004; 20,9:1026–1031.
5.
FangG, WeiserB, KuikenC, PhilpottSM, Rowland-JonesS, PlummerF, KimaniJ, ShiB, KaulR, BwayoJ, AnzalaO, BurgerH. Recombination following superinfection by HIV-1. AIDS, 2004; 18,2:153–159.
6.
HuDJ, SubbaraoS, VanichseniS, MockPA, RamosArtur, NguyenL, ChaowanachanT, GriensvenF, ChoopanyaK, MastroTD, TapperoJW. Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS, 2005; 19,3:303–308.
7.
FultzPN. HIV-1 superinfections: Omens for vaccine efficacy?AIDS, 2004; 18,1:115–119.
8.
ShineD, MollB, EmesonE, SpiglandI, HarrisC, SmallCB, FriedlandG, WeissSH, BodnerAJ. Serologic, immunologic, and clinical features of parenteral drug users from contrasting populations. Am J Drug Alcohol Abuse, 1987; 13,4:401–412.
9.
PierikLT, MurphyEL. The clinical significance of HTLV-I and HTLV-II infection in the AIDS epidemic. AIDS Clin Rev, 1991; 1:39–57.
10.
KhabbazRF, OnoratoIM, CannonRO, HartleyTM, RobertsB, HoseinB, KaplanJE. Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med, 1992; 326,6:375–380.
11.
WiktorSZ, CannonRO, AtkinsonWL, LutzB, HookEW, BlattnerWA, QuinnTC. Infection with HTLV-II and -II in sexually transmitted disease clinics in Baltimore and New Orleans. J Infect Dis, 1992; 165,5:920–924.
12.
BriggsNC, BattjesRJ, CantorKP, BlattnerWA, YellinFM, WilsonS, RitzAL, WeissSH, GoedertJJ. Seroprevalence of HTLV-II infection, with or without HIV-1 coinfection, among US intravenous drug users. J Infect Dis, 1995; 172,1:51–58.
13.
BessingerR, BeilkeM, KissingerP, JarrottC, TabakOF. Retroviral coinfections at a New Orleans HIV outpatient clinic. J AIDS Human Retrovirol, 1997; 14,1:67–71.
14.
KaplanJE, KhabbazRF. The epidemiology of human T-lymphotropic virus types I and II. Rev Med Virol, 1993; 3:137.
15.
DezzuttiCS, LalRB. Human T-cell lymphotropic virus types I and II. Manual of Clinical Microbiology. MurrayPR, BaronKJ, PfallerMA. American Society for Microbiology: Washington, DC, 1999; 871.
16.
AraujoA, SheehyN, TakahashiH, HallWW. Concomitant infections with human immunodeficiency virus type 1, human T-lymphotropic virus types 1, 2. Polymicrobial Diseases. BrogdenKA, GuthmillerJM. ASM Press: Washington, DC, 2002Chapter 5.
17.
SchreiberGB, MurphyEL, HortonJA, WrightDJ, GarfeinR, ChienHC, NassCC. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: The retrovirus epidemiology donor study. NHLBI retrovirus epidemiology donor study. J Acquir Immune Defic Syndr Hum Retrovirol, 1997; 14,3:263–271.
18.
BarcellosNT, FuchsSC, MondiniLG, MurphyEL. Human T lymphotropic virus type I/II infection: Prevalence and risk factors in individuals testing for HIV in counseling centers from Southern Brazil. Sex Trans Dis, 2006; 33,5:302–306.
19.
MurphyEL, WatanabeK, NassCC, OwnbyH, WilliamsA, NemoG. Evidence among blood donors for a 30-year old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis, 1999; 180,6:1777–1783.
20.
ZellaD, MoriL, SalaM, FerranteP, CasoliC, MagnaniG, AchilliG, CattaneoE, LoriF, BertazzoniU. HTLV-II infection in Italian drug abusers. Lancet, 1990; 336,8714:575–576.
21.
FukushimaY, TakahashiH, HallWW, NakasoneT, NakataS, SongP, DucDD, HienB, QuangNX, TrinhTN, NishiokaK, KitamuraK, KomuroK, VahlneA, HondaM. Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in south Vietnam. AIDS Res Hum Retroviruses, 1995; 11,5:637–645.
22.
EdlinBR, IrwinKL, FaruqueS, McCoyCB, WordC, SerranoY, InciardiJA, BowserBP, SchillingRF, HolmbergSD. and the Multicenter Crack Cocaine and HIV Infection Study Team. Intersecting epidemics––crack cocaine use and HIV infection among inner-city young adults. N Engl J Med, 1994; 331,21:1422–1427.
23.
Substance Abuse and Mental Health Services Administration (SAMHSA) Report. National survey shows a rise in illicit drug use from 2008 to 2010SAMHSA News ReportSeptember8, 2011. http://www.samhsa.gov.
24.
PoieszBJ, BuscettiFW, GazdarAF, BunnPA, MinnaJD, GalloRC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA, 1980; 77,12:7415–7419.
25.
HinumaY, NagataK, HanaokaM, NakaiM, MatsumotoT, KinoshitaKI, ShirahawaS, MiyoshiI. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA, 1981; 78,10:6476–6480.
26.
MiyoshiI, KubonishiI, YoshimotoS, AkagiT, OhtsukiY, ShiraishiY, NagataK, HinumaY. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature, 1981; 294,5843:770–771.
27.
YoshidaM, SeikiM, YamaguchiK, TakatsukiK. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA, 1984; 81,8:2534–2537.
28.
KalyanaramanVS, SarngadharanMG, Robert-GuroffM, MiyoshiI, GoldeD, GalloRC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science, 1982; 218,4572:571–573.
29.
GessainA, BarinF, VernantJC, GoutO, MaursL, CalenderA, de TheG. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet, 1985; 2,8452:407–410.
30.
OsameM, UsukuK, IzumoS, IjichiN, AmitaniH, IgataA, MatsumotoM, TaraM. HTLV-I associated myelopathy, a new entity. Lancet, 1986; 1,8488:1031–1032.
31.
Barre-SinoussiF, ChermannJC, ReyF, NugeyreMT, ChamaretS, GruestJ, DauguetC, Axler-BlinC, Vezinet-BrunF, RouziouxC, RozenbaumW, MontagnierL. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)Science, 1983; 220,4599:868–871.
32.
BroderS, GalloRC. A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med, 1984; 311,20:1992–1297.
33.
HaradaS, KoyangiY, YamamotoN. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science, 1985; 229,4713:563–566.
CoffinJ, HaaseA, LevyJA, MontagnierL, OroszlanS, TeichN, TeminH, ToyoshimaK, VarmusH, VogtP, WeissR. What to call the AIDS virus? [letter]Nature, 1986; 821,6065:10.
36.
GondaMA, Wong-StaalF, GalloRC, ClementsJE, NarayanO, GildenRV. Sequence homology and morphologic similarity of HTLV-III and Visna virus, a pathogenic lentivirus. Science, 1985; 227,4683:173–177.
37.
PopovicM, Read-ConnoleE, GalloRC. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet, 1984; 2,8417–8418:1472–1473.
38.
KoenigS, GendelmanHE, OrensteinJM, Dal CantoMC, PezeshkpourGH, YungbluthM, JanottF, AksamitA, MartinMA, FauciAS. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science, 1986; 233,4768:1089–1093.
39.
SeikiM, HattoriS, HirayamaY, YoshidaM. Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci USA, 1983; 80,12:3618–3622.
40.
ShimotohnoK, TakahashiY, ShimizuN, GojoboriT, GoldeDW, ChenISY, MiwaM, SugimuraT. Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: An open reading frame for the protease gene. Proc Natl Acad Sci USA, 1985; 82,10:3101–3105.
41.
RatnerL, HaseltineW, PatarcaR, LivakKJ, StarcichB, JosephsSF, DoranE, RafalskiJA, WhitehornEA, BaumeisterKet al.Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature, 1985; 313,6000:277–284.
42.
SchüpbachJ, GildenR, GondaMA, SarngadharanMG, GalloRC. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science, 1984; 224,4648:503–505.
43.
EssexM, McLaneMF, LeeTH, TachibanaN, MullinsJI, KreissJ, KasperCK, PoonM-C, LandayA, SteinSF, FrancisDP, CabradillaC, LawrenceDN, EvattBL. Antibodies to human T-cell leukemia virus membrane antigens (HTLV-MA) in hemophiliacs. Science, 1983; 221,4615:1061–1064.
44.
SarngadharanMG, BruchL, PopovicM, GalloRC. Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III)Proc Natl Acad Sci USA, 1985; 82,10:3481–3484.
45.
CaseyJM, KimY, AndersenPR, WatsonKF, FoxJL, DevareSG. Human T-cell lymphotropic virus type III: Immunologic characterization and primary structure analysis of the major internal protein, p24. J Virol, 1985; 55,2:417–423.
46.
AbeT, KinoshitaT, MatsudaJ, RyuT, TingRC, AokiT, Robert-GuroffM, MiyakoshiH, GalloRC. Detection of antibodies to HTLV-I and -III in sera from Japanese hemophiliacs. Cancer Res, 1985; 45,9 Suppl:4621s–4623s.
47.
Robert-GuroffM, BlayneyDW, SafaiB, LangeM, GelmannM, GuttemanEP, MansellJW, GoedtertPW, GroopmanJL, SteigbigelJEet al.HTLV-1-specific antibody in AIDS patients and others at risk. Lancet, 1984; 2,8395:128–131.
48.
Robert-GuroffM, WeissSH, GironJA, JenningsAM, GinzburgHM, MargolisIB, BlattnerWA, GalloRC. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA, 1986; 255,22:3133–3137.
49.
BartholomewC, BlattnerW, CleghornF. Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet, 1987; 2,8573:1469.
50.
HattoriT, KoitoA, TakatsukiK, IkematsuS, MatsudaJ, MoriH, FukuiM, AkashiK, MatsumotoK. Frequent infection with human T-cell lymphotropic virus type I in patients with AIDS but not in carriers of human immunodeficiency virus type 1. J Acquir Immune Defic Syndr Hum Retrovirol, 1989; 2,3:272–276.
51.
HarperME, KaplanMH, MarselleLM, PahwaSG, ChaytKJ, SarngadharanMG, Wong-StaalF, GalloRC. Concomitant infection with HTLV-I and HTLV-III in a patient with T8 lymphoproliferative disease. N Eng J Med, 1986; 315,17:1073–1078.
52.
ShibataD, BrynesRK, RabinowitzA, HansonCA, SlovakM, SpiraTJ, GillP. Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1)Ann Intern Med, 1989; 111,11:871–875.
53.
PageJB, LaiS, ChitwoodDD, KlimasNG, SmithPC, FletcherMA. HTLV-I/II positivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet, 1990; 335,8703:1439–1441.
54.
HeneineW, KhabbazRF, LalRB, KaplanJE. Sensitive and specific polymerase chain reaction assays for diagnosis of human T-cell lymphotropic virus type I (HTLV-I) and HTLV-III infections in HTLV-I/II-seropositive individuals. J Clin Micro, 1992; 30,6:1605–1607.
55.
EhrlichGD, GlaserJB, LaVigneK, QuanD, MildvanD, SninskyJJ, KwokS, PapsideroL, PoieszBJ. Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: Type-specific identification of HTLVs by polymerase chain reaction. Blood, 1989; 74,5:1658–1664.
56.
LeeH, SwansonP, ShortyVS. High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science, 1989; 244,4903:471–475.
57.
WattelE, MariottiM, AgisF, GordienE, ProuO, CourouceAM, RougerP, Wain-HobsonS, ChenIS, LefrereJJ. Human T lymphotropic virus (HTLV) type I and II DNA amplification in HTLV-I/II-seropositive blood donors of the French West Indies. J Infect Dis, 1992; 165,2:369–372.
58.
WiktorSZ, AlexanderSS, ShawGM, WeissSH, MurphyEL, WilksRJ, ShortlyVJ, HanchardB, BlattnerWA. Distinguishing between HTLV-I and HTLV-II by Western blot [letter]Lancet, 1990; 335,8704:1533.
GotuzzoE, EscamillaJ, PhillipsIA, SanchezJ, WignallFS, AntigoniJ. The impact of human T-lymphotrophic virus type I/II infection on the prognosis of sexually acquired cases of acquired immunodeficiency syndrome. Arch Intern Med, 1992; 152,7:1429–1373.
61.
CleghornFR, BlattnerWA. Does human T-cell lymphotropic virus type I and human immunodeficiency virus type 1 coinfection accelerate acquired immunodeficiency syndrome? The jury is still out (editorial)Arch Intern Med, 1992; 152,7:1372–1373.
62.
VolberdingPA. HIV, HTLV-I, and CD4+ lymphocytes: Troubles in the relationship (editorial)JAMA, 1994; 271,5:392–393.
63.
HershowRC, GalaiN, FukudaK, GraberJ, VlahovD, RezzaG, KleinRS, Des JarlaisDC, VitekC, KhabbazR, FreelsS, ZuckermanR, PezzottiP, KaplanJE. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis, 1996; 174,2:309–317.
64.
SchechterM, MoultonLH, HarrisonLH. HIV Viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol, 1997; 15,4:308–311.
65.
HillSA, LloydPA, McDonaldS, WykoffJ, DerseD. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J Infect Dis, 2003; 188,2:424–427.
66.
PowderlyWG. Significance of HIV/HTLV coinfection? Editorial. http://www.medscape.com/viewarticle/4406402002.
67.
TurciM, PilottiE, RonziP, MagnaniG, BoschiniA, ParisiSG, ZipetoD, LisaA, CasoliC, BertazzoniU. Coinfection with HIV-1 and human T-cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol, 2006; 41,1:100–106.
68.
BassiniS, LopezM, ToroC, JiménezV, SempereJM, SorianoV, BenitoJM. Influence of human T cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients. Clin Infect Dis, 2007; 44,1:105–110.
69.
BritesC, SampaioJ, OliveiraA. HIV/Human T-cell lymphotropic virus coinfection revisited: Impact on AIDS progression. AIDS Rev, 2009; 11,1:8–16.
70.
BritesC, AlencarR, GusmãoR, PedrosoC, NettoEM, Pedral-SampaloD, BardaróR. Co-infection with HTLV-1 is associated with a shorter survival time for HIV-1-infected patients in Bahia, Brazil. AIDS, 2001; 15,15:2053–2055.
71.
PedrosoC, NettoEM, WeyllN, BritesC. Coinfection by HIV-1 and human lymphotropic virus type 1 in Brazilian children is strongly associated with a shorter survival time. J Acquir Immune Defic Syndr Hum Retrovirol, 2011; 57,Suppl 3:S208–S211.
72.
BeilkeMA, TheallKP, O'BrienM, ClaytonJL, BenjaminSM, WinsorEL, KissingerPJ. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infec Dis, 2004; 39,2:256–263.
73.
BeilkeMA, JapaS, Moeller-HadiC, Martin-SchildS. Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfected patients. Clin Infect Dis, 2005; 41,6:e57–e63.
74.
BeilkeMA, Traina-DorgeVL, SiroisM, BhuiyanA, MurphyEL, WallsJM, FaganR, WinsorEL, KissingerPJ. Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection. Clin Infect Dis, 2007; 44,9:1229–1234.
75.
CassebJ, Posada-VergaraMP, MontanheiraP, FukumoriLMI, OlahI, SmidJ, DuartoAJ, Penaiva de OliveiraAC. T CD4+ cell counts among patients co-infected with human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus type 1 (HTLV-1): High prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM)Revist Instit Med Trop Sao Paulo, 2007; 49,4:231–233.
76.
CasoliC, PilottiE, BertazzoniU. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev, 2007; 9,3:140–149.
MurphyEL, GrantRM, KroppJ, OlivieraA, LeeT-H, BuschMP. Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. J Acquir Immune Defic Syndr Hum Retrovirol, 2003; 33,5:655–656.
79.
CesaireR, DeheeA, LezinA, DesireN, BourdonneO, DantinF, BeraO, SmadjaD, AbelS, CabieA, SobeskyG, NicolasJC. Quantification of HTLV type I and HIV type 1 DNA load in coinfected patients: HIV type 1 infection does not alter HTLV type I proviral amount in the peripheral blood compartment. AIDS Res Hum Retrovirus, 2001; 17,9:799–805.
BanerjeeP, RochfordR, AntelJ, CanuteG, WrzesinskiS, SieburgM, FeuerG. Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells. J Virol, 2007; 81,4:1690–1700.
82.
YamanoY, NagaiM, BrennanM, MoraCA, SoldanSS, TomaruU, TakenouchiN, IzumoS, OsameM, JacobsonS. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP)Blood, 2002; 99,1:88–94.
83.
HiguchiM, FujiiM. Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis. Retrovirology, 2009; 6,117:1–11.
84.
BertazzoniU, TurciM, AvesaniF, DiiGennaroG, BidoiaC, RomanelliMG. Intracellular localization and cellular factors interaction of HTLV-1 and HTLV-2 Tax proteins: Similarities and functional differences. Viruses, 2011; 3,5:541–560.
85.
LewisMJ, GautierVW, WangXP, KaplanMH, HallWW. Spontaneous production of C-C chemokines by individuals infected with human T lymphotropic virus type II (HTLV-II) alone and HTLV-II/HIV-1 coinfected individuals. J Immunol, 2000; 165,7:4127–4132.
86.
CasoliC, VicenziE, CimarelliA, MagnaniG, CiancianainiP, CattaneoE, Dall'AlgioPP, PoliG, BertazzoniU. HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1a. Blood, 2000; 95,9:2760–2769.
87.
PilottiE, ElviriL, VicenziE, Bertazzoni Um ReMC, AllibardiS, PoliG, CasoliC. Postgenomic up-regulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood, 2007; 109,5:1850–1856.
88.
DragicT, LitwinV, AllawayGP, MartinSR, HuangY, NagashimaKA, CayananC, MaddonPJ, KoupRA, MooreJP, PaxtonWA. HIV-1 entry into CD4+ cells is mediated by the chemokines receptor CC-CKR-5. Nature, 1996; 381,6584:667–673.
89.
BatesP. Chemokine receptors and HIV-1: An attractive pair?Cell, 1996; 86,1:1–3.
90.
PaxtonWA, MartinSR, TseD, O'BrienTR, SkurnickJ, VanDevanterNL, PadianN, BraunJF, KotlerDP, WolinskySM, KoupRA. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med, 1996; 2,4:412–417.
91.
CocchiF, DeVicoAL, Garzino-DemoA, AryaSK, GalloRC, LussoP. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factor produced by CD8+ T cells. Science, 1995; 270,5243:1811–1815.
92.
Garzino-DemoA, MossRB, MargolickJB, CleghornF, SillA, BlattnerWA, CocchiF, CarloDJ, DeVicoAL, GalloRC. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA, 1999; 96,21:11986–11991.
93.
CocchiF, DeVicoAL, YarchoanR, RedfieldR, CleghornF, BlattnerWA, Garzino-DemoA, Colombini-HatchS, MargolisD, GalloRC. Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA, 2000; 97,25:13812–13817.
94.
BarriosCS, AbuerreishM, LairmoreMD, WuL, CastilloL, GiamC-Z, BeilkeMA. Recombinant human T-cell leukemia virus types 1 and 2 Tax proteins induce high levels of CC-chemokines and downregulate CCR5 in human peripheral blood mononuclear cells. Viral Immunol, 2011; 24,6:1–11.
95.
MatsuokaM, GreenPL. The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology, 2009; 6:71.
96.
HalinM, DouceronE, ClercI, JournoC, KoNL, LandryS, MurphyEL, GessainA, LemassonI, MesnardJ-M, BarbeauB, MahieuxR. Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. Blood, 2009; 114,12:2724–2438.
